Don't miss our holiday offer - up to 50% OFF!
Don't miss our holiday offer - up to 50% OFF!
Triple-Action Metabolic Compound
GLP-3 (RT)
LY3437943
GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in laboratory research. Purity ≥ 99%, independently verified by third-party HPLC testing.
Dosage
Quantity
1
BUNDLE & SAVE
Secure payment via
Pay
VISA
Disc
Amex
Complimentary shipping
on all orders above $150
Breakage coverage
included at no cost
Encrypted checkout
256-bit SSL secured
Certificate of Analysis
Independently verified by ILS Laboratories · ISO/IEC 17025 accredited
99.81%
PURITY
✓ Passed full QC panel
FULL QC PANEL7× tested
Purity (HPLC)99.81% ✓
Net Peptide Content10.19mg
Identity (HPLC)Retatrutide ✓
HPLC Conformitymean 99.74% ✓
Heavy Metals (ICP-MS)Not Detected ✓
Sterility (PCR)No Growth ✓
Endotoxin (USP <85>)< 0.05 EU/mL
ISO/IEC 17025 ACCREDITED
📄 View COA
99.69%
PURITY
✓ Passed full QC panel
FULL QC PANEL7× tested
Purity (HPLC)99.69% ✓
Net Peptide Content20.31mg
Identity (HPLC)Retatrutide ✓
HPLC Conformitymean 99.61% ✓
Heavy Metals (ICP-MS)Not Detected ✓
Sterility (PCR)No Growth ✓
Endotoxin (USP <85>)< 0.05 EU/mL
ISO/IEC 17025 ACCREDITED
📄 View COA
99.77%
PURITY
✓ Passed full QC panel
FULL QC PANEL7× tested
Purity (HPLC)99.77% ✓
Net Peptide Content31.81mg
Identity (HPLC)Retatrutide ✓
HPLC Conformitymean 99.72% ✓
Heavy Metals (ICP-MS)Not Detected ✓
Sterility (PCR)No Growth ✓
Endotoxin (USP <85>)< 0.05 EU/mL
ISO/IEC 17025 ACCREDITED
📄 View COA
99.80%
PURITY
✓ Passed full QC panel
99.80%
PURITY
✓ Passed full QC panel
Compound Information
Technical specifications
🧬 MOLECULAR PROFILE
What is GLP-3 (RT)?
TypeSynthetic peptide
CAS Number2381089-83-2
Molecular Weight4,731 g/mol
Amino Acids39
Fatty Acid ChainC20 diacid
📦 STORAGE REQUIREMENTS
Stability Information
Avoid freeze/thaw cycles
Protect from light
Keep refrigerated
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
Sources & References
Peer-reviewed research on the triple-agonist mechanism
NEW ENGLAND JOURNAL OF MEDICINE
Phase 2 efficacy data for the GLP-3 (RT) triple agonist in obesity
2023 · Jastreboff AM, et al.
View Source ↗
THE LANCET
GLP-3 (RT) in adults with type 2 diabetes — phase 2 findings
2023 · Rosenstock J, et al.
View Source ↗
NATURE MEDICINE
Liver fat reduction with GLP-3 (RT) in metabolic dysfunction-associated steatotic liver disease
2024 · Sanyal AJ, et al.
View Source ↗
LANCET DIABETES & ENDOCRINOLOGY
Body composition outcomes with GLP-3 (RT) therapy
2025 · Coskun T, et al.
View Source ↗
⚠️ IMPORTANT RESEARCH NOTICE
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings referenced on this page are drawn from peer-reviewed journals and official publications. They are provided for educational context only and should not be read as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.